23andMe Investor Presentation Deck

The GSK'608 Program is a Prime Example of the Value 23andMe Brings to Drug Discovery and Development Inhibition of CD96 leads to immune activation and tumor growth inhibition in non-clinical models GSK'608 is a high affinity monoclonal antibody against CD96 GSK'608 is currently being evaluated in an ongoing Phase 1 study In January 2022, 23andMe elected to take a royalty option on GSK'608. As a result, GSK is now solely responsible for the development of GSK'608. Copyright © 2022 23and Me, Inc. 23and Me 47

View entire presentation